康哲药业拟分拆德镁医药上市,聚焦皮肤健康驶入增长“快车道”

环球财富网
Yesterday

近日,康哲药业建议启动分拆,拟推动旗下皮肤业务子公司德镁医药于香港联交所主板独立上市,引发资本市场广泛关注。在医药行业日益向专业化、精准化发展的趋势下,聚焦于皮肤健康领域的德镁医药凭借深耕细分赛道、差异化产品布局以及强劲的商业化能力,展现出显著的成长潜力。资料显示,德镁医药2022年至2024年收入复合年增长率达26.8%,2024年收入达6.18亿元人民币。其核心产品在银屑病、特应性皮炎等领域的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10